Leap Therapeutics rises as cancer therapy shows promise in mid-stage study

Cypherpunk Technologies

17/01/2024 11:43

** Shares of drug developer Leap Therapeutics  LPTX.O  rise
2.9% to $3.57 premarket
    ** Co said late on Monday, its therapy candidate DKN-01 in
combination with cancer drug bevacizumab and chemotherapy
generated clinically meaningful tumor reductions in patients
with advanced colorectal cancer in a mid-stage study
    ** Colorectal cancer starts in the colon or the rectum
    ** The therapy is also being tested in a type of uterine
cancer, gastric cancer, lung cancer and prostate cancer
    ** Up to Tuesday's close, LPTX stock has fallen 40.5% in the
last 12 months

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))